Title : PCA3 as a second-line biomarker in a prospective controlled randomized opportunistic prostate cancer screening programme.

Pub. Date : 2017 Jun

PMID : 28342633






2 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Moreover, if we had applied PCA3-35 to avoid IBx, 14.7% PCa and 9.1% of clinical significant PCa patients would not have been diagnosed during this FU. o-iodoxybenzoic acid prostate cancer associated 3 Homo sapiens
2 CONCLUSIONS: When PCA3-35 is used as a second-line biomarker when PSA >=3ng/ml and DRE is normal, IBx could be avoided in 12.5% less than if ERSPC RC-3 is used and would reduce the false negative cases by 36.2%. o-iodoxybenzoic acid prostate cancer associated 3 Homo sapiens